PL3045474T3 - Środki terapeutyczne do leczenia chorób związanych z niepożądaną proliferacją komórek - Google Patents
Środki terapeutyczne do leczenia chorób związanych z niepożądaną proliferacją komórekInfo
- Publication number
- PL3045474T3 PL3045474T3 PL16155009T PL16155009T PL3045474T3 PL 3045474 T3 PL3045474 T3 PL 3045474T3 PL 16155009 T PL16155009 T PL 16155009T PL 16155009 T PL16155009 T PL 16155009T PL 3045474 T3 PL3045474 T3 PL 3045474T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- therapeutic agents
- cell proliferation
- diseases related
- undesired cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2093—Leukaemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G01N33/575—
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200900928A ES2363358B1 (es) | 2009-04-03 | 2009-04-03 | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| PCT/EP2010/054499 WO2010115868A2 (en) | 2009-04-03 | 2010-04-06 | Therapeutic agents for the treatment of diseases associated with undesired cell proliferation |
| EP10713619A EP2414394A2 (en) | 2009-04-03 | 2010-04-06 | Therapeutic agents for the treatment of diseases associated with undesired cell proliferation |
| EP16155009.0A EP3045474B1 (en) | 2009-04-03 | 2010-04-06 | Therapeutic agents for the treatment of diseases associated with undesired cell proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3045474T3 true PL3045474T3 (pl) | 2021-08-09 |
Family
ID=42342718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16155009T PL3045474T3 (pl) | 2009-04-03 | 2010-04-06 | Środki terapeutyczne do leczenia chorób związanych z niepożądaną proliferacją komórek |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10100112B2 (pl) |
| EP (2) | EP3045474B1 (pl) |
| JP (5) | JP6207836B2 (pl) |
| KR (6) | KR20180079470A (pl) |
| CN (2) | CN107964043A (pl) |
| AU (1) | AU2010233791B2 (pl) |
| BR (1) | BRPI1015369A2 (pl) |
| CA (1) | CA2757680C (pl) |
| CY (1) | CY1124148T1 (pl) |
| DK (1) | DK3045474T3 (pl) |
| EA (1) | EA201101450A1 (pl) |
| ES (2) | ES2363358B1 (pl) |
| HR (1) | HRP20210352T1 (pl) |
| HU (1) | HUE054196T2 (pl) |
| IL (1) | IL215467A (pl) |
| LT (1) | LT3045474T (pl) |
| MX (1) | MX336903B (pl) |
| PL (1) | PL3045474T3 (pl) |
| PT (1) | PT3045474T (pl) |
| SG (2) | SG175032A1 (pl) |
| SI (1) | SI3045474T1 (pl) |
| SM (1) | SMT202100153T1 (pl) |
| WO (1) | WO2010115868A2 (pl) |
| ZA (1) | ZA201107215B (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ565172A (en) * | 2005-07-19 | 2012-12-21 | Stemgen S P A | Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS |
| EP2371860A1 (en) | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| JP2015071566A (ja) * | 2013-10-03 | 2015-04-16 | 住友ベークライト株式会社 | Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物 |
| US20180169100A1 (en) * | 2014-03-11 | 2018-06-21 | Godavari Biorefineries Limited | Cancer Stem Cell Targeting Compounds |
| WO2016004060A2 (en) * | 2014-06-30 | 2016-01-07 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
| CN106687134A (zh) * | 2014-09-10 | 2017-05-17 | 加利福尼亚大学董事会 | 通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤 |
| EP3067422B1 (en) * | 2015-03-13 | 2024-07-31 | Sabanci Üniversitesi | Ct-1 inhibitors |
| WO2016154203A1 (en) | 2015-03-23 | 2016-09-29 | Evestra, Inc. | Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents |
| EP3173483A1 (en) | 2015-11-27 | 2017-05-31 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Agents for the treatment of diseases associated with undesired cell proliferation |
| US10583191B2 (en) | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
| IL267450B (en) | 2016-12-19 | 2022-07-01 | Mosaic Biomedicals S L U | Antibodies against lif and their uses |
| CA3099406A1 (en) * | 2018-05-14 | 2019-11-21 | Medimmune Limited | Antibodies against lif and dosage forms thereof |
| AU2019291307B2 (en) * | 2018-06-18 | 2024-04-04 | Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats | Combination of LIF inhibitors and platinum-based antineoplastic agents for use in treating cancer |
| CA3103763A1 (en) * | 2018-06-18 | 2019-12-26 | Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats | Methods for improving response to anti-lif antibody treatment in individuals with cancer |
| WO2020056349A2 (en) * | 2018-09-13 | 2020-03-19 | Evestra, Inc. | Lif/lifr antagonist oncology and nonmalignant diseases |
| WO2020213665A1 (ja) * | 2019-04-17 | 2020-10-22 | 国立大学法人広島大学 | Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤 |
| CN111020030A (zh) * | 2019-12-03 | 2020-04-17 | 中山大学 | 一种骨肉瘤干细胞标志物及其应用、试剂盒 |
| EP3988116A1 (en) * | 2020-10-23 | 2022-04-27 | Consejo Superior De Investigaciones Científicas (CSIC) | Methods and compositions for the treatment of hematologic malignancies |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| ATE115999T1 (de) | 1987-12-15 | 1995-01-15 | Gene Shears Pty Ltd | Ribozyme. |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| GB9004890D0 (en) * | 1990-03-05 | 1990-05-02 | Heath John K | Leukaemia inhibitory factor |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05304986A (ja) * | 1992-04-28 | 1993-11-19 | Tosoh Corp | ｇｐ１３０蛋白質に対するモノクロ−ナル抗体 |
| AU4231393A (en) * | 1992-05-08 | 1993-12-13 | Genentech Inc. | Antibodies to leukemia inhibitory factor |
| GB9413316D0 (en) | 1994-07-01 | 1994-08-24 | Cancer Res Campaign Tech | Novel proteins |
| US6251588B1 (en) | 1998-02-10 | 2001-06-26 | Agilent Technologies, Inc. | Method for evaluating oligonucleotide probe sequences |
| US20050147609A1 (en) | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| CN1763097B (zh) | 1999-01-15 | 2011-04-13 | 杰南技术公司 | 具有改变的效应功能的多肽变体 |
| DK1156823T3 (da) * | 1999-02-12 | 2009-01-19 | Scripps Research Inst | Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier |
| US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| CA2480052A1 (en) | 2002-04-01 | 2003-10-16 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| EP2236614A3 (en) * | 2002-08-15 | 2011-01-26 | Genzyme Corporation | Brain endothelial cell expression patterns |
| US20060078533A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004067778A2 (en) * | 2003-01-28 | 2004-08-12 | University Of South Florida | Differentially expressed genes in large granular lymphocyte leukemia |
| WO2005030803A1 (en) * | 2003-09-29 | 2005-04-07 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic molecules |
| CA2566286A1 (en) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
| WO2010025414A2 (en) * | 2008-08-29 | 2010-03-04 | Genentech, Inc. | Diagnostics and treatments for vegf-independent tumors |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| US10583191B2 (en) * | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
-
2009
- 2009-04-03 ES ES200900928A patent/ES2363358B1/es not_active Withdrawn - After Issue
-
2010
- 2010-04-06 KR KR1020187018827A patent/KR20180079470A/ko not_active Ceased
- 2010-04-06 PL PL16155009T patent/PL3045474T3/pl unknown
- 2010-04-06 SG SG2011071834A patent/SG175032A1/en unknown
- 2010-04-06 KR KR1020177030504A patent/KR20170121319A/ko not_active Ceased
- 2010-04-06 EP EP16155009.0A patent/EP3045474B1/en active Active
- 2010-04-06 KR KR1020227007752A patent/KR20220035978A/ko not_active Ceased
- 2010-04-06 EP EP10713619A patent/EP2414394A2/en not_active Ceased
- 2010-04-06 SI SI201032059T patent/SI3045474T1/sl unknown
- 2010-04-06 DK DK16155009.0T patent/DK3045474T3/da active
- 2010-04-06 HU HUE16155009A patent/HUE054196T2/hu unknown
- 2010-04-06 CN CN201711070081.2A patent/CN107964043A/zh active Pending
- 2010-04-06 CN CN2010800246730A patent/CN102574918A/zh active Pending
- 2010-04-06 WO PCT/EP2010/054499 patent/WO2010115868A2/en not_active Ceased
- 2010-04-06 KR KR1020197022597A patent/KR20190093691A/ko not_active Ceased
- 2010-04-06 SM SM20210153T patent/SMT202100153T1/it unknown
- 2010-04-06 LT LTEP16155009.0T patent/LT3045474T/lt unknown
- 2010-04-06 KR KR1020117026088A patent/KR20120100703A/ko not_active Ceased
- 2010-04-06 EA EA201101450A patent/EA201101450A1/ru unknown
- 2010-04-06 US US13/138,804 patent/US10100112B2/en active Active
- 2010-04-06 CA CA2757680A patent/CA2757680C/en active Active
- 2010-04-06 JP JP2012502710A patent/JP6207836B2/ja active Active
- 2010-04-06 SG SG10202010568RA patent/SG10202010568RA/en unknown
- 2010-04-06 AU AU2010233791A patent/AU2010233791B2/en not_active Ceased
- 2010-04-06 ES ES16155009T patent/ES2864639T3/es active Active
- 2010-04-06 KR KR1020207017470A patent/KR102373754B1/ko active Active
- 2010-04-06 PT PT161550090T patent/PT3045474T/pt unknown
- 2010-04-06 BR BRPI1015369-1A patent/BRPI1015369A2/pt not_active Application Discontinuation
- 2010-04-06 MX MX2011010425A patent/MX336903B/es active IP Right Grant
-
2011
- 2011-10-02 IL IL215467A patent/IL215467A/en active IP Right Grant
- 2011-10-03 ZA ZA2011/07215A patent/ZA201107215B/en unknown
-
2015
- 2015-09-11 JP JP2015178986A patent/JP2016040255A/ja active Pending
-
2018
- 2018-08-14 JP JP2018152551A patent/JP2019006784A/ja active Pending
- 2018-08-28 US US16/115,191 patent/US20190211095A1/en not_active Abandoned
-
2020
- 2020-02-04 JP JP2020016672A patent/JP2020090522A/ja active Pending
- 2020-08-24 US US17/001,530 patent/US11999782B2/en active Active
-
2021
- 2021-03-02 HR HRP20210352TT patent/HRP20210352T1/hr unknown
- 2021-03-18 CY CY20211100232T patent/CY1124148T1/el unknown
- 2021-11-17 JP JP2021186785A patent/JP7197665B2/ja active Active
-
2024
- 2024-05-01 US US18/652,603 patent/US20240400667A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3045474T3 (pl) | Środki terapeutyczne do leczenia chorób związanych z niepożądaną proliferacją komórek | |
| IL262075B (en) | Treatment of inflammatory diseases using placental stem cells | |
| CY2014006I2 (el) | Μεθοδοι θεραπευτικης αγωγης χρησιμοποιωντας γλυκοπεγκυλιωμενο g-csf | |
| RU2557654C3 (ru) | Терапевтические агенты для снижения уровней паратиреоидного гормона | |
| DK3130923T3 (da) | Terapeutiske fremgangsmåder i forbindelse med cancerstamceller | |
| IL200368A0 (en) | Treatment of diseases characterized by inflammation | |
| EP2613786A4 (en) | TREATMENT OF DISEASES | |
| HUE039506T2 (hu) | Ibat inhibitorok májbetegségek kezelésére | |
| EP2613795A4 (en) | TREATMENT OF DISEASES | |
| PL2435825T3 (pl) | Sposoby leczenia chorób | |
| IL216399A0 (en) | Pharmaceutical composition for the treatment of heart diseases | |
| ME03508B (me) | Kombinovana terapija za liječenje dijabetesa | |
| BRPI0821779A2 (pt) | tratamento terapêutico de câncer | |
| EP2310006A4 (en) | CANCER TREATMENT | |
| PL2717692T3 (pl) | Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych | |
| EP2247297A4 (en) | THERAPEUTIC TREATMENT OF LUNG DISEASES | |
| ZA200905364B (en) | Treatment of diseases characterized by inflammation | |
| GB0904427D0 (en) | Treatment of diseases related to hyperactivity of the complement system | |
| EP2608808A4 (en) | TREATMENT OF NEOPLASIS DISEASES | |
| EP2554163A4 (en) | THERAPEUTIC ACTIVE FOR NEURODEGENERATIVE DISEASES | |
| PL3447070T3 (pl) | Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w | |
| SMT201600479B (it) | Nuove soluzioni terapeutiche per il trattamento di condizioni neuroinfiammatorie | |
| PL2467140T3 (pl) | Lapatynib do leczenia raka | |
| BRPI1013903A2 (pt) | tratamentos terapêuticos utilizando centaquina | |
| PL3363439T3 (pl) | Kompozycje terapeutyczne do leczenia cukrzycowej polineuropatii symetrycznej |